Press Releases


May 28, 2015
CytomX to Present at the Jefferies 2015 Global Healthcare Conference

May 27, 2015
CytomX Expands Executive Leadership Team

May 6, 2015
CytomX to Present Probody Overview at the Credit Suisse Antibody Day

April 13, 2015
CytomX to Present Overview of Precision Cancer Immunotherapies at the Jefferies Immuno-Oncology Summit

March 19, 2015
CytomX Appoints Immuno-Oncology Leader Rachel Humphrey, M.D., to Board of Directors

March 2, 2015
CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates

Februray 26, 2015
CytomX to Present at Cowen and Company 35th Annual Health Care Conference

January 6, 2015
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments

January 5, 2015
CytomX Expands Leadership Team with Addition of Michael Kavanaugh, M.D., as Chief Scientific Officer and Head of Research and Early Development

May 27, 2014
Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets

March 26, 2014
CytomX Therapeutics to Present Data from Anti-Jagged Probody Program at Upcoming AACR Annual Meeting 2014

January 9, 2014
CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets


October 22, 2013
CytomX Therapeutics Presents Data for First-in-Class Jagged Probody™ Program at AACR-NCI-EORTC International Conference

October 16, 2013
Publication in Science Translational Medicine Highlights Enhanced Therapeutic Index of CytomX Probody™ Therapeutic Compared to Traditional Antibody

October 1, 2013
CytomX Therapeutics to Present at 12th Annual BIO Investor Forum

September 24, 2013
CytomX Therapeutics Named a 2013 “Fierce 15” Biotech Company by FierceBiotech

July 16, 2013
CytomX Announces Appointment of Krishna Polu, M.D., as Chief Medical Officer; Promotion of Debanjan Ray, MBA, to Vice President, Business Development

June 6, 2013
CytomX Announces Global Strategic Collaboration with Pfizer to Develop and Commercialize Multiple Probody™-Drug Conjugates in Oncology

June 3, 2013
CytomX Therapeutics Named a 2013 Red Herring Top 100 North America Tech Startup

May 7, 2013
CytomX Therapeutics Named a Finalist for the 2013 Red Herring Top 100 North America Award

April 3, 2013
New Data Highlighting CytomX's Probody Platform and EGFR Probody Drug Conjugate to be Presented at the AACR Annual Meeting 2013


July 31, 2012
CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate

March 6, 2012
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors


October 6, 2011
CytomX Therapeutics Promotes Henry Lowman, Ph.D., to Chief Scientific Officer

August 11, 2011
CytomX Announces Appointment of Sean McCarthy as Chief Executive Officer

January 5, 2011
CytomX Therapeutics Appoints Sean McCarthy as Chief Business Officer


November 12, 2010
CytomX Therapeutics Awarded Two Federal Research Grants under the Qualifying Therapeutic Discovery Project (QTDP) Program

September 23, 2010
CytomX Therapeutics Completes $30 Million Series B Financing